IMPACT BIOMEDICAL INC
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
IBO$4.33+5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
**Impact BioMedical, Inc. and Subsidiaries **
As of December 31,
| 2023 | 2022 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,000 | $2,000 |
| Current portion of notes receivable | 203,000 | 16,000 |
| Other receivables | 128,000 | - |
| Prepaid expenses and other current assets | - | 104,000 |
| Total current assets | 332,000 | 122,000 |
| Property, plant and equipment, net | 287,000 | 276,000 |
| Other investments | - | 782,000 |
| Notes receivable | - | 190,000 |
| Goodwill | 25,093,000 | 25,093,000 |
| Other intangible assets, net | 18,921,000 | 20,034,000 |
| Total assets | $44,633,000 | $46,497,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $832,000 | $539,000 |
| Accrued expenses | 230,000 | 63,000 |
| Note payable, related party | 12,074,000 | 9,991,000 |
| Total current liabilities | 13,136,000 | 10,593,000 |
| Deferred tax liability, net | 3,235,000 | 3,235,000 |
| Total Liabilities | 16,371,000 | 13,828,000 |
| Commitments and contingencies (Note 12) | - | - |
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 100,000,000 shares authorized, 60,496,041 shares issued and outstanding (0 shares issued and outstanding on December 31, 2022); Liquidation value $0.001 per share, $60,000, ($0 aggregate on December 31, 2022). | 60,000 | - |
| Common stock, $0.001 par value; 4,000,000,000 shares authorized, 10,000,000 shares issued and outstanding (70,496,041 on December 31, 2022) | 10,000 | 70,000 |
| Additional paid-in capital | 38,113,000 | 38,113,000 |
| Accumulated deficit | (12,961,000) | (8,625,000) |
| Total stockholders’ equity of the company | 25,222,000 | 29,558,000 |
| Non-controlling interest in subsidiary | 3,040,000 | 3,111,000 |
| Total stockholder’s equity | 28,262,000 | 32,669,000 |
| Total liabilities and stockholders’ equity | $44,633,000 | $46,497,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.